Pfizer Signs Agreement With Schering AG to License Compounds

Pfizer and Schering AG have signed a license agreement granting Pfizer a worldwide license to Schering AG's ADP receptor antagonist program. Under the agreement, Pfizer will have exclusive rights to develop and market oral antiplatelet compounds developed by Schering AG's U.S. affiliate Berlex. Schering will receive an upfront fee, milestone payments and royalties on sales of any compounds successfully commercialized under the agreement. Specific financial terms were not announced.
BioSpace